Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.

Journal of hepatology - 1 Feb 2015

Gordon Stuart C, Muir Andrew J, Lim Joseph K, Pearlman Brian, Argo Curtis K, Ramani Ananthakrishnan, Maliakkal Benedict, Alam Imtiaz, Stewart Thomas G, Vainorius Monika, Peter Joy, Nelson David R, Fried Michael W, Reddy K Rajender

Abstract excerpt

BACKGROUND & AIMS: The safety profiles of boceprevir and telaprevir in the treatment of chronic hepatitis C, administered in academic and community centres across the United States, were evaluated. METHODS: In 90 medical centres, patients with chronic HCV received pegylated interferon, ribavirin, and either telaprevir or boceprevir per local standard of care. Demographic, adverse event, clinical, and virological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Oligopeptides

Share to Proline

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 25218788
DOI: 10.1016/j.jhep.2014.08.052
PMCID: PMC4586075

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.PMID 25218788Read ↗

Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting.Semantic proximity Read ↗

Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.Semantic proximity Read ↗

Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score.Semantic proximity Read ↗

Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans.Semantic proximity Read ↗

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.Semantic proximity Read ↗

Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.Semantic proximity Read ↗

Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?Semantic proximity Read ↗

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.Semantic proximity Read ↗

A review of standard and newer treatment strategies in hepatitis C.Semantic proximity Read ↗

A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy.Semantic proximity Read ↗

Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study.Semantic proximity Read ↗

Advances in the management of hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.